Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin making decisions about coverage not only for Amjevita but for all the other Humira biosimilars [...]
In the world of employee benefits, organizations and brokers often find themselves struggling to get a clear picture of the entire health benefits landscape. For self-funded groups, the challenge lies in managing [...]
Any views or opinions presented in these articles are solely those of the author and do not necessarily represent those of the company. AHP accepts no liability for the content of these articles, or for the consequences of any actions taken on the basis of the information provided unless that information is subsequently confirmed in writing.